337 related articles for article (PubMed ID: 31806772)
1. Radiation Dosimetry in
Jackson PA; Hofman MS; Hicks RJ; Scalzo M; Violet J
J Nucl Med; 2020 Jul; 61(7):1030-1036. PubMed ID: 31806772
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry of
Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
[No Abstract] [Full Text] [Related]
3. An Intrapatient Dosimetry Comparison of
Rinscheid A; Gäble A; Wienand G; Pfob C; Dierks A; Kircher M; Trepel M; Weckermann D; Lapa C; Bundschuh RA
J Nucl Med; 2023 Dec; 64(12):1918-1924. PubMed ID: 37770108
[TBL] [Abstract][Full Text] [Related]
4. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
[TBL] [Abstract][Full Text] [Related]
5. First-in-human study of
Zang J; Fan X; Wang H; Liu Q; Wang J; Li H; Li F; Jacobson O; Niu G; Zhu Z; Chen X
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):148-158. PubMed ID: 30090965
[TBL] [Abstract][Full Text] [Related]
6. Estimation of absorbed dose to salivary glands in mCRPC patients undergoing 177 Lu- PSMA-617 radioligand therapy using quantitative SPECT-CT at single time point: a single-center feasibility study.
Kaur K; Nagi S; Satapathy S; Aggarwal P; Sood A; Mittal BR
Nucl Med Commun; 2024 Feb; 45(2):115-120. PubMed ID: 37982573
[TBL] [Abstract][Full Text] [Related]
7. Radiation Dosimetry for
Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
[TBL] [Abstract][Full Text] [Related]
8. Lesion Dosimetry for [
Grkovski M; O'Donoghue JA; Imber BS; Andl G; Tu C; Lafontaine D; Schwartz J; Thor M; Zelefsky MJ; Humm JL; Bodei L
J Nucl Med; 2023 Nov; 64(11):1779-1787. PubMed ID: 37652541
[TBL] [Abstract][Full Text] [Related]
9. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
[TBL] [Abstract][Full Text] [Related]
10. Pretherapeutic Comparative Dosimetry of
Feuerecker B; Chantadisai M; Allmann A; Tauber R; Allmann J; Steinhelfer L; Rauscher I; Wurzer A; Wester HJ; Weber WA; d'Alessandria C; Eiber M
J Nucl Med; 2022 Jun; 63(6):833-839. PubMed ID: 34531260
[TBL] [Abstract][Full Text] [Related]
11. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
12. Preparation of
Guleria M; Amirdhanayagam J; Sarma HD; Rallapeta RP; Krishnamohan VS; Nimmagadda A; Ravi P; Patri S; Kalawat T; Das T
Biomed Res Int; 2021; 2021():1555712. PubMed ID: 34845436
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Response to
Hohberg M; Reifegerst M; Drzezga A; Wild M; Schmidt M
J Nucl Med; 2023 Nov; 64(11):1758-1764. PubMed ID: 37652546
[TBL] [Abstract][Full Text] [Related]
14. Toward Single-Time-Point Image-Based Dosimetry of
Brosch-Lenz J; Delker A; Völter F; Unterrainer LM; Kaiser L; Bartenstein P; Ziegler S; Rahmim A; Uribe C; Böning G
J Nucl Med; 2023 May; 64(5):767-774. PubMed ID: 36657980
[TBL] [Abstract][Full Text] [Related]
15. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.
Fendler WP; Reinhardt S; Ilhan H; Delker A; Böning G; Gildehaus FJ; Stief C; Bartenstein P; Gratzke C; Lehner S; Rominger A
Oncotarget; 2017 Jan; 8(2):3581-3590. PubMed ID: 27683041
[TBL] [Abstract][Full Text] [Related]
16. Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.
Barna S; Haug AR; Hartenbach M; Rasul S; Grubmüller B; Kramer G; Blaickner M
Clin Nucl Med; 2020 Sep; 45(9):661-667. PubMed ID: 32604113
[TBL] [Abstract][Full Text] [Related]
17. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
[TBL] [Abstract][Full Text] [Related]
19. Dual-Time-Point Posttherapy
Straub M; Kupferschläger J; Serna Higuita LM; Weissinger M; Dittmann H; la Fougère C; Fiz F
J Nucl Med; 2023 Sep; 64(9):1431-1438. PubMed ID: 37414446
[No Abstract] [Full Text] [Related]
20. Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [
Hardiansyah D; Yousefzadeh-Nowshahr E; Kind F; Beer AJ; Ruf J; Glatting G; Mix M
J Nucl Med; 2024 Apr; 65(4):566-572. PubMed ID: 38423787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]